KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Accumulated Expenses (2020 - 2023)

Historic Accumulated Expenses for AbCellera Biologics (ABCL) over the last 4 years, with Q3 2023 value amounting to $3.1 million.

  • AbCellera Biologics' Accumulated Expenses fell 8263.94% to $3.1 million in Q3 2023 from the same period last year, while for Sep 2023 it was $3.1 million, marking a year-over-year decrease of 8263.94%. This contributed to the annual value of $19.3 million for FY2022, which is 1403.63% down from last year.
  • Latest data reveals that AbCellera Biologics reported Accumulated Expenses of $3.1 million as of Q3 2023, which was down 8263.94% from $3.1 million recorded in Q2 2023.
  • AbCellera Biologics' Accumulated Expenses' 5-year high stood at $50.6 million during Q2 2022, with a 5-year trough of $595000.0 in Q3 2021.
  • In the last 4 years, AbCellera Biologics' Accumulated Expenses had a median value of $19.7 million in 2021 and averaged $19.7 million.
  • As far as peak fluctuations go, AbCellera Biologics' Accumulated Expenses surged by 289529.41% in 2022, and later tumbled by 9387.99% in 2023.
  • Quarter analysis of 4 years shows AbCellera Biologics' Accumulated Expenses stood at $27.1 million in 2020, then decreased by 17.08% to $22.5 million in 2021, then dropped by 14.04% to $19.3 million in 2022, then plummeted by 84.01% to $3.1 million in 2023.
  • Its Accumulated Expenses was $3.1 million in Q3 2023, compared to $3.1 million in Q2 2023 and $3.1 million in Q1 2023.